109
Participants
Start Date
June 20, 2020
Primary Completion Date
June 26, 2023
Study Completion Date
August 21, 2023
Dupilumab
solution for injection subcutaneous
Placebo
Solution for injection subcutaneous
Investigational Site Number : 1580001, Taipei
Investigational Site Number : 1580003, Tainan City
Investigational Site Number : 1580004, Kaohsiung City
Investigational Site Number : 1000015, Sofia
Investigational Site Number : 1000005, Sofia
Investigational Site Number : 1000003, Sofia
Investigational Site Number : 1000006, Sofia
Investigational Site Number : 1000011, Sofia
Investigational Site Number : 1000010, Sofia
Investigational Site Number : 1000002, Sofia
Investigational Site Number : 2080002, Copenhagen
Investigational Site Number : 2080003, Copenhagen Nv
Investigational Site Number : 1000013, Dupnitsa
Investigational Site Number : 2080001, Hvidovre
Investigational Site Number : 1000004, Montana
Investigational Site Number : 1000018, Plovdiv
Investigational Site Number : 1000012, Plovdiv
Investigational Site Number : 1000007, Stara Zagora
Investigational Site Number : 1000008, Rousse
Investigational Site Number : 2080006, Aarhus N
Investigational Site Number : 6820006, Riyadh
Investigational Site Number : 6820001, Riyadh
Investigational Site Number : 6820002, Riyadh
Investigational Site Number : 6820010, Riyadh
Investigational Site Number : 7240002, Santiago de Compostela
Investigational Site Number : 3800004, Rozzano
Investigational Site Number : 6820004, Jeddah
Investigational Site Number : 7240005, Madrid
Investigational Site Number : 7240003, Madrid
American Health Research Site Number : 8400005, Charlotte
VitaLink Research - Spartanburg Site Number : 8400011, Spartanburg
~Spartanburg Medical Research Site Number : 8400004, Spartanburg
Medical University of South Carolina - Pulmonary & Critical Care Clinical Research Program Site Number : 8400009, Charleston
VitaLink Research-Greenville Site Number : 8400013, Greenville
Investigational Site Number : 6820008, Dammam
Investigational Site Number : 1580002, Taichung
Investigational Site Number : 3800003, Cona
Investigational Site Number : 8040007, Ternopil
University of Michigan Site Number : 8400002, Ann Arbor
Investigational Site Number : 3800001, Pisa
Investigational Site Number : 8040003, Chernivtsi
Investigational Site Number : 8040002, Kharkiv
The Lung Research Center Site Number : 8400010, Chesterfield
Investigational Site Number : 8040005, Odesa
University of Kansas School of Medicine Site Number : 8400008, Kansas City
Investigational Site Number : 8040001, Ivano-Frankivsk
Allianz Research Institute Site Number : 8400020, Westminster
Velocity Clinical Research, Medford Site Number : 8400014, Medford
Investigational Site Number : 6420003, Timișoara
Investigational Site Number : 6420006, Cluj-Napoca
Investigational Site Number : 6420001, Cluj-Napoca
Investigational Site Number : 6420007, Oradea
Investigational Site Number : 6420008, Brasov
Investigational Site Number : 6420005, Bragadiru
Investigational Site Number : 2500001, Montpellier
Investigational Site Number : 6200004, Coimbra
Investigational Site Number : 6200005, Guimarães
Investigational Site Number : 6200006, Lisbon
Investigational Site Number : 6200003, Porto
Investigational Site Number : 6200001, Porto
Investigational Site Number : 7240001, Barcelona
Investigational Site Number : 7520001, Lund
Investigational Site Number : 8040004, Kyiv
Investigational Site Number : 8260001, Leicester
Investigational Site Number : 8260002, Bradford
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY